ClinicalTrials.gg
CompletedNCT01414075Updated Oct 1, 2021Results posted

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

A Phase 2 interventional study of Roxadustat and Oral Iron in Dialysis and Anemia, sponsored by FibroGen. Completed at 7 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
35th of 43
60 · median 154
Started
2011
with 2 others
Phase 2
8 of 43
none open now
Registered
5th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 35th largest by enrollment, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 5th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.

Read the detailed description

Participants on hemodialysis (HD) will be randomized to 3 treatment arms (A, B, and C) of in a 1:1:1 ratio to receive no iron supplementation, oral iron supplementation, and IV iron supplementation, respectively, in addition to roxadustat. At the same time, participants on peritoneal dialysis (PD) will be enrolled into Arm D. Arm E will enroll either HD or PD participants, and is an optional, confirmatory/supplemental treatment arm with flexible dosing and flexible iron supplementation based on the evaluation of data from the previous 4 treatment arms.

Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [40 to 60 kilograms {kg}], medium weight [>60 to 90 kg], and heavy weight [>90 to 140 kg] participants will receive 60, 100, and 140 milligrams [mg] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 140, 200, and 300 mg for low, medium, and high weight participants, respectively) during Weeks 5 and 9, depending on the hemoglobin (Hb) level and rate of Hb rise in the previous 4 weeks.

03

Conditions studied

  • Dialysis
  • Anemia

Keywords

  • Kidney
  • ESRD
  • Renal
  • End-Stage Renal Disease
  • Anemia
  • Oral anemia treatment
  • Hemoglobin levels
  • Hemodialysis
  • Peritoneal
  • HD
  • PD
  • Hb
  • Erythropoietin
  • Blood count
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving HD or PD for native kidney end-stage renal disease (ESRD) for 2 weeks to 4 months, prior to randomization
  • Mean of the 2 most recent values during the screening period, obtained at least 7 days apart, must be \<10.0 grams (g)/deciliter (dL), with a difference of ≤1.0 g/dL between the 2 values
  • Body weight 40 to 140 kilograms (kg)

Exclusion criteria

Exclusion Criteria:

  • Previously received erythropoiesis-stimulating agents
  • Received IV iron within 4 weeks of randomization
  • Received red blood cell transfusion within 8 weeks prior to randomization or anticipated need for transfusion during the treatment period
  • Positive for any of the following: (HIV), surface antigen (HBsAg), or anti- virus antibody (anti-HCV Ab)
  • History of chronic liver disease
  • infection
  • Class III or IV congestive heart failure
  • History of , except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
  • Chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
  • History of other blood disorders
  • Active hemolysis or diagnosis of hemolytic syndrome
  • Known bone marrow fibrosis
  • Uncontrolled or symptomatic secondary hyperparathyroidism
  • History of alcohol or drug abuse within a year prior to randomization, or anticipated inability to avoid consumption of more than 3 alcoholic beverages per day
  • History of allergy or sensitivity to oral or IV iron therapy
  • Seizure disorder or receiving anti-epilepsy medication for seizure disorder within 12 weeks prior to randomization
  • Pregnant or breast-feeding females
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm A + E (Participants on HD): Roxadustat Only, No Iron

    Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.

    Drug: Roxadustat

  • Experimental
    Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg

    Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.

    Drug: Roxadustat · Drug: Oral Iron

  • Experimental
    Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg

    Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection \[for example, Ferrlecit®\] or equivalent) once a week for 12 weeks.

    Drug: Roxadustat · Drug: IV Iron

  • Experimental
    Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg

    Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.

    Drug: Roxadustat · Drug: Oral Iron

Interventions

  • Tiered, weight-based dosing per schedule specified in the arm.

    Also known as: FG-4592

  • Administered per oral dose and schedule specified in the arm.

  • Administered per IV dose and schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Maximum Change From Baseline in Hb During Weeks 3-13

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. This outcome measure is derived from the maximum change from baseline during Weeks 3-13, without last observation carried forward (LOCF) imputation.

    Time frame: Baseline, Weeks 3-13

Secondary outcomes

  1. Mean Change From Baseline in Hb During Weeks 2-5, 6-9, and 10-13

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Baseline, Weeks 2-5, 6-9, and 10-13

  2. Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Week 3 to 13

  3. Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Week 3 to 13

  4. Number of Participants With a Hb Response, Defined as an Increase in Hb by ≥1.0 g/dL From Baseline, by Weeks 5, 9, and 13

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Weeks 5, 9, and 13

  5. Number of Participants Who Achieved Maximum Hb During Weeks 3-13

    Time frame: Weeks 3-13

  6. Number of Participants With a Maximum Change From Baseline in Hb During Weeks 3-13

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. The number of participants who fall within the following categories of maximum change are reported: \<1 g/dL, ≥1 g/dL, 1 to \<2 g/dL, 2 to \<3 g/dL, \>3 to \<4 g/dL, ≥4 g/dL.

    Time frame: Baseline, Weeks 3-13

  7. Median Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Baseline up to Week 13

  8. Weekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

    Time frame: Baseline up to Week 13

  9. Number of Participants Requiring Dose Increase at Weeks 5 and 9

    Number of participants requiring dose increase due to any reasons is reported.

    Time frame: Weeks 5 and 9

  10. Number of Participants Requiring Dose Reduction or Dose Discontinuation Due to Excessive Erythropoiesis

    Number of participants requiring dose reduction or dose discontinuation due to excessive erythropoiesis is reported.

    Time frame: Weeks 5 and 9

  11. Change From Baseline in Ferritin at Week 13

    Baseline was defined as the average of the last 2 values prior to the first dose administration.

    Time frame: Baseline, Week 13

  12. Change From Baseline in Transferrin Saturation (TSAT) at Week 13

    Time frame: Baseline, Week 13

  13. Change From Baseline in Reticulocyte Hemoglobin Content at Week 13

    Time frame: Baseline, Week 13

  14. Number of Participants With Mean Hb Values 11.0-13.0 g/dL at Weeks 6-9 and 10-13

    Time frame: Weeks 6-9 and 10-13

  15. Number of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL

    Time frame: Weeks 10-13

  16. Number of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL

    Time frame: Weeks 10-13

  17. Number of Participants With Mean Hb Values in Excess of 13.0 and 14.0 g/dL at Weeks 6-9 and 10-13

    Time frame: Weeks 6-9 and 10-13

  18. Number of Participants With Mean Hb Values <10.0 g/dL at Weeks 6-9 and 10-13

    Time frame: Weeks 6-9 and 10-13

  19. Number of Participants Requiring Rescue Treatment With an Erythropoiesis-Stimulating Agent (ESA), Red Blood Cells (RBC) Transfusion, or IV Iron (Excluding Arm C)

    Number of participants requiring rescue treatment with an ESA, RBC transfusion, or IV Iron (Excluding Arm C) was reported.

    Time frame: Baseline up to Week 13

  20. Number of Participants Requiring Therapeutic Phlebotomy

    Number of participants who required therapeutic phlebotomy due to TEAE of abnormal erythropoiesis is reported.

    Time frame: Baseline up to Week 13

  21. Number of Participants Withdrawn From the Study Due to Inadequate Efficacy

    Number of participants withdrawn from the study due to inadequate efficacy is reported.

    Time frame: Baseline up to Week 16

  22. Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 9 and 13

    The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). Higher score indicated a better health state. Baseline is defined as the last non-missing value prior to the first dose administration.

    Time frame: Baseline, Weeks 9 and 13

  23. Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score at Weeks 9 and 13

    FACT-An is composed of 27 core items which assess participant's function in 4 domains and 20 anemia-related items, grouped into 5 subscales as follows: Physical well-being (PWB): 7 items; Social/family well-being (SWB): 7 items; Emotional well-being (EWB): 6 items; Functional well-being (FWB): 7 items; and Anemia: 20 items. All FACT-An items were rated as: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much. Each subscale score was the sum of scores for the items in the subscale. The FACT-An total score was the sum of all 5 subscale scores, ranging from 0 (worst) - 188 (best). Higher scores represented better quality of life. Baseline is defined as the last non-missing value prior to the first dose administration.

    Time frame: Baseline, Weeks 9 and 13

  24. Number of Participants With Potentially Clinically Significant Laboratory Tests

    Criteria for the potential clinical significance included: bilirubin (µmol/L) \>1.5 \* upper limit of normal (ULN), potassium (mmol/L) \>1.2 \* ULN, neutrophils (\*10\^9/L) ≤1, protein (g/L) \>1.1 \* ULN, leukocytes (\*10\^9/L) ≤2.5 or ≥15.

    Time frame: Baseline up to Week 16

  25. Number of Participants With TEAEs

    An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. A summary of other nonserious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 16

07

Results

Posted Oct 1, 2021

Participant flow

Participants on hemodialysis (HD) were randomized to one of the 3 arms A, B, or C in 1:1:1 ratio to receive roxadustat with either no, per oral (PO), or intravenous (IV) iron supplementation, respectively. Participants on peritoneal dialysis (PD) were enrolled into Arm D and received roxadustat with PO iron supplementation.

Participant flow — Overall Study
MilestoneArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Started24121212
Efficacy evaluable (ee) population23121010
Completed21121010
Not completed3022
Withdrew: Adverse event1010
Withdrew: Death1001
Withdrew: Withdrawal by subject0001
Withdrew: Other than specified1010

Outcome measures

PrimaryMaximum Change From Baseline in Hb During Weeks 3-13

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. This outcome measure is derived from the maximum change from baseline during Weeks 3-13, without last observation carried forward (LOCF) imputation.

Time frame:
Baseline, Weeks 3-13
Reported as:
Mean · grams/deciliter (g/dL)
Maximum Change From Baseline in Hb During Weeks 3-13
grams/deciliter (g/dL)Arm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline8.1 ± 0.28.5 ± 0.38.4 ± 0.38.7 ± 0.2
Change at Weeks 3-132.8 ± 0.23.5 ± 0.53.5 ± 0.43.3 ± 0.2
Statistical analysis
  • Arm A + E (Participants on HD): Roxadustat Only, No Iron vs Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg · ANCOVA · p = 0.0757 (Threshold for significance at 0.05 level.)
  • Arm A + E (Participants on HD): Roxadustat Only, No Iron vs Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg · ANCOVA · p = 0.0630 (Threshold for significance at 0.05 level.)
  • Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg vs Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg · ANCOVA · p = 0.8653 (Threshold for significance at 0.05 level.)
  • Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg vs Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg · ANCOVA · p = 0.8982 (Threshold for significance at 0.05 level.)
SecondaryMean Change From Baseline in Hb During Weeks 2-5, 6-9, and 10-13

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Baseline, Weeks 2-5, 6-9, and 10-13
Reported as:
Mean · g/dL
Mean Change From Baseline in Hb During Weeks 2-5, 6-9, and 10-13
g/dLArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline8.1 ± 0.28.5 ± 0.38.4 ± 0.38.7 ± 0.2
Change at Weeks 2-51.1 ± 0.11.1 ± 0.21.0 ± 0.20.8 ± 0.3
Change at Weeks 6-92.0 ± 0.22.3 ± 0.42.0 ± 0.41.8 ± 0.4
Change at Weeks 10-132.1 ± 0.22.7 ± 0.53.0 ± 0.42.4 ± 0.2
SecondaryNumber of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Week 3 to 13
Reported as:
Count of participants · Participants
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL10889
SecondaryNumber of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Week 3 to 13
Reported as:
Count of participants · Participants
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL1710810
SecondaryNumber of Participants With a Hb Response, Defined as an Increase in Hb by ≥1.0 g/dL From Baseline, by Weeks 5, 9, and 13

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Weeks 5, 9, and 13
Reported as:
Count of participants · Participants
Number of Participants With a Hb Response, Defined as an Increase in Hb by ≥1.0 g/dL From Baseline, by Weeks 5, 9, and 13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Week 521977
Week 9221099
Week 1322111010
SecondaryNumber of Participants Who Achieved Maximum Hb During Weeks 3-13
Time frame:
Weeks 3-13
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Maximum Hb During Weeks 3-13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
<10 g/dL6120
10 to <11 g/dL7301
11 to 13 g/dL10559
>13 to 14 g/dL0130
>14 g/dL0200
SecondaryNumber of Participants With a Maximum Change From Baseline in Hb During Weeks 3-13

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. The number of participants who fall within the following categories of maximum change are reported: \<1 g/dL, ≥1 g/dL, 1 to \<2 g/dL, 2 to \<3 g/dL, \>3 to \<4 g/dL, ≥4 g/dL.

Time frame:
Baseline, Weeks 3-13
Reported as:
Count of participants · Participants
Number of Participants With a Maximum Change From Baseline in Hb During Weeks 3-13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
<1 g/dL1100
≥1 g/dL22111010
1 to <2 g/dL4220
2 to <3 g/dL9205
>3 to <4 g/dL7243
≥4 g/dL2542
SecondaryMedian Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Baseline up to Week 13
Reported as:
Median · weeks
Median Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)
weeksArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Median Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)4.0 (3.0 to 4.0)4.0 (3.0 to 6.0)4.0 (3.0 to 6.0)4.0 (3.0 to 8.0)
SecondaryWeekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.

Time frame:
Baseline up to Week 13
Reported as:
Mean · mg/kg
Weekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)
mg/kgArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Weekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)4.2 ± 0.54.2 ± 1.24.5 ± 1.44.3 ± 1.4
SecondaryNumber of Participants Requiring Dose Increase at Weeks 5 and 9

Number of participants requiring dose increase due to any reasons is reported.

Time frame:
Weeks 5 and 9
Reported as:
Count of participants · Participants
Number of Participants Requiring Dose Increase at Weeks 5 and 9
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Week 52324
Week 98535
SecondaryNumber of Participants Requiring Dose Reduction or Dose Discontinuation Due to Excessive Erythropoiesis

Number of participants requiring dose reduction or dose discontinuation due to excessive erythropoiesis is reported.

Time frame:
Weeks 5 and 9
Reported as:
Count of participants · Participants
Number of Participants Requiring Dose Reduction or Dose Discontinuation Due to Excessive Erythropoiesis
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Dose reduced at Week 53535
Dose interrupted at Week 51000
Dose reduced at Week 91030
Dose interrupted at Week 91001
SecondaryChange From Baseline in Ferritin at Week 13

Baseline was defined as the average of the last 2 values prior to the first dose administration.

Time frame:
Baseline, Week 13
Reported as:
Mean · micrograms/liter (µg/L)
Change From Baseline in Ferritin at Week 13
micrograms/liter (µg/L)Arm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline156.4 ± 12.9162.5 ± 30.8182.0 ± 27.4137.4 ± 27.0
Change at Week 13-119.7 ± 12.2-51.1 ± 25.2-25.2 ± 33.5-65.1 ± 29.4
SecondaryChange From Baseline in Transferrin Saturation (TSAT) at Week 13
Time frame:
Baseline, Week 13
Reported as:
Mean · percentage of transferrin
Change From Baseline in Transferrin Saturation (TSAT) at Week 13
percentage of transferrinArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline18.8 ± 0.819.0 ± 1.018.1 ± 1.519.3 ± 1.8
Change at Week 13-7.4 ± 1.42.6 ± 2.50.7 ± 2.9-1.6 ± 2.6
SecondaryChange From Baseline in Reticulocyte Hemoglobin Content at Week 13
Time frame:
Baseline, Week 13
Reported as:
Mean · picogram (pg)
Change From Baseline in Reticulocyte Hemoglobin Content at Week 13
picogram (pg)Arm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline31.0 ± 0.331.6 ± 0.531.5 ± 0.530.4 ± 0.4
Change at Week 13-2.2 ± 0.7-1.9 ± 0.9-1.0 ± 0.6-0.2 ± 0.6
SecondaryNumber of Participants With Mean Hb Values 11.0-13.0 g/dL at Weeks 6-9 and 10-13
Time frame:
Weeks 6-9 and 10-13
Reported as:
Count of participants · Participants
Number of Participants With Mean Hb Values 11.0-13.0 g/dL at Weeks 6-9 and 10-13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Weeks 6-96545
Weeks 10-135257
SecondaryNumber of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL
Time frame:
Weeks 10-13
Reported as:
Count of participants · Participants
Number of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL5257
SecondaryNumber of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL
Time frame:
Weeks 10-13
Reported as:
Count of participants · Participants
Number of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL15779
SecondaryNumber of Participants With Mean Hb Values in Excess of 13.0 and 14.0 g/dL at Weeks 6-9 and 10-13
Time frame:
Weeks 6-9 and 10-13
Reported as:
Count of participants · Participants
Number of Participants With Mean Hb Values in Excess of 13.0 and 14.0 g/dL at Weeks 6-9 and 10-13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Week 6-90000
Week 10-130110
SecondaryNumber of Participants With Mean Hb Values <10.0 g/dL at Weeks 6-9 and 10-13
Time frame:
Weeks 6-9 and 10-13
Reported as:
Count of participants · Participants
Number of Participants With Mean Hb Values <10.0 g/dL at Weeks 6-9 and 10-13
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Week 6-910423
Week 10-138321
SecondaryNumber of Participants Requiring Rescue Treatment With an Erythropoiesis-Stimulating Agent (ESA), Red Blood Cells (RBC) Transfusion, or IV Iron (Excluding Arm C)

Number of participants requiring rescue treatment with an ESA, RBC transfusion, or IV Iron (Excluding Arm C) was reported.

Time frame:
Baseline up to Week 13
Reported as:
Count of participants · Participants
Number of Participants Requiring Rescue Treatment With an Erythropoiesis-Stimulating Agent (ESA), Red Blood Cells (RBC) Transfusion, or IV Iron (Excluding Arm C)
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Blood transfusion for severe anemia0010
Blood transfusion for gastrointestinal bleeding1000
IV iron for acute iron deficiency10—0
IV iron for a treatment-emergent adverse event (TEAE) of thrombocytosis10—0
SecondaryNumber of Participants Requiring Therapeutic Phlebotomy

Number of participants who required therapeutic phlebotomy due to TEAE of abnormal erythropoiesis is reported.

Time frame:
Baseline up to Week 13
Reported as:
Count of participants · Participants
Number of Participants Requiring Therapeutic Phlebotomy
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants Requiring Therapeutic Phlebotomy0100
SecondaryNumber of Participants Withdrawn From the Study Due to Inadequate Efficacy

Number of participants withdrawn from the study due to inadequate efficacy is reported.

Time frame:
Baseline up to Week 16
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From the Study Due to Inadequate Efficacy
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants Withdrawn From the Study Due to Inadequate Efficacy0000
SecondaryChange From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 9 and 13

The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). Higher score indicated a better health state. Baseline is defined as the last non-missing value prior to the first dose administration.

Time frame:
Baseline, Weeks 9 and 13
Reported as:
Mean · units on a scale
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 9 and 13
units on a scaleArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Physical functioning subscore: Baseline38.8 ± 2.340.7 ± 3.241.2 ± 3.440.8 ± 1.8
Physical functioning subscore: Change at Week 94.8 ± 1.61.6 ± 2.51.5 ± 2.53.4 ± 1.2
Physical functioning subscore: Change at Week 135.2 ± 1.81.8 ± 2.14.8 ± 1.82.3 ± 1.3
Vitality subscore: Baseline46.3 ± 2.248.2 ± 4.149.0 ± 3.546.8 ± 3.6
Vitality subscore: Change at Week 92.9 ± 1.8-1.0 ± 4.03.4 ± 2.85.9 ± 3.0
Vitality subscore: Change at Week 133.9 ± 1.71.6 ± 3.73.1 ± 2.36.2 ± 1.6
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score at Weeks 9 and 13

FACT-An is composed of 27 core items which assess participant's function in 4 domains and 20 anemia-related items, grouped into 5 subscales as follows: Physical well-being (PWB): 7 items; Social/family well-being (SWB): 7 items; Emotional well-being (EWB): 6 items; Functional well-being (FWB): 7 items; and Anemia: 20 items. All FACT-An items were rated as: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much. Each subscale score was the sum of scores for the items in the subscale. The FACT-An total score was the sum of all 5 subscale scores, ranging from 0 (worst) - 188 (best). Higher scores represented better quality of life. Baseline is defined as the last non-missing value prior to the first dose administration.

Time frame:
Baseline, Weeks 9 and 13
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score at Weeks 9 and 13
units on a scaleArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Baseline123.5 ± 6.8118.9 ± 10.9128.8 ± 11.3122.8 ± 7.9
Change at Week 98.2 ± 4.54.0 ± 7.21.9 ± 9.812.8 ± 6.9
Change at Week 137.3 ± 4.35.9 ± 6.95.1 ± 8.912.9 ± 7.4
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Tests

Criteria for the potential clinical significance included: bilirubin (µmol/L) \>1.5 \* upper limit of normal (ULN), potassium (mmol/L) \>1.2 \* ULN, neutrophils (\*10\^9/L) ≤1, protein (g/L) \>1.1 \* ULN, leukocytes (\*10\^9/L) ≤2.5 or ≥15.

Time frame:
Baseline up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Tests
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Bilirubin1000
Potassium2101
Neutrophils0110
Protein1000
Leukocytes1010
SecondaryNumber of Participants With TEAEs

An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. A summary of other nonserious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With TEAEs
ParticipantsArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Number of Participants With TEAEs16635

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A + E (Participants on HD): Roxadustat Only, No Iron—3/24 (12.5%)6/24 (25%)
Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg—1/12 (8.3%)4/12 (33.3%)
Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg—0/12 (0%)0/12 (0%)
Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg—3/12 (25%)2/12 (16.7%)
Most frequent serious events
Most frequent serious events
EventArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
Chemical peritonitisInjury, poisoning and procedural complications0/240/120/122/12
Cardiac failure acuteCardiac disorders0/240/120/121/12
Device related infectionInfections and infestations0/241/120/120/12
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications1/241/120/120/12
Cardiac failure chronicCardiac disorders1/240/120/120/12
Myocardial infarctionCardiac disorders1/240/120/120/12
Gastrointestinal haemorrhageGastrointestinal disorders1/240/120/120/12
Pyelonephritis chronicInfections and infestations1/240/120/120/12
Most frequent other events
Most frequent other events
EventArm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg
HypertensionVascular disorders1/243/120/122/12
Transferrin saturation decreasedInvestigations3/241/120/120/12
PhlebitisVascular disorders2/241/120/120/12

Baseline characteristics

Safety population included all participants who received any dose of study drug.

Age, Continuous
Age, Continuous(years)Arm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgTotal
Mean49.6 ± 17.746.8 ± 14.653.1 ± 12.651.4 ± 12.450.1 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm A + E (Participants on HD): Roxadustat Only, No IronArm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgArm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mgArm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mgTotal
Female9371029
Male1595231
08

Study locations

7 sites
  • Northridge, California, United States
  • Yuba City, California, United States
  • Detroit, Michigan, United States
  • Hong Kong, Hong Kong
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
  • Singapore, Singapore
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Jan 2013, 17 months.

Results were first posted in Oct 2021, 8 years 8 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 17 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2011
First posted
Aug 11, 2011
StartActual
Jul 21, 2011
Primary completionActual
Jan 10, 2013
CompletionActual
Jan 10, 2013
Results first posted
Oct 1, 2021
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01414075
Lead sponsor
FibroGen
Collaborators
Astellas Pharma Inc
Responsible party
Sponsor
First posted
Aug 11, 2011
Start date
Jul 21, 2011
Primary completion
Jan 10, 2013
Completion
Jan 10, 2013
Results posted
Oct 1, 2021
Last update
Oct 1, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion